The dismally poor 5 year survival rate of less than 6% in pancreatic ductal adenocarcinoma (PDAC) increases to ~50% with early stage PDAC making early detection critically important. Metabolic characterization of patient plasma samples provides a unique opportunity to identify biomarkers to assist in routine screening to detect of PDAC. Here, in a preliminary study, we have characterized the metabolic profiles of plasma samples from normal, benign, and PDAC patients. Even with a limited sample we identified a significant increase in β-hydroxybutyrate, acetate, acetoacetate, lactate and pyruvate in PDAC compared to normal plasma.
This abstract and the presentation materials are available to members only; a login is required.